Create a Report
Please provide report title
Please provide location
Please provide details
Get alerts and updates for your case! Your contact information is not shown on the website.
This information is not shown on the website. We can notify you of updates, and may contact you for more information to help resolve or follow up on your issue.
Please provide email or phone
Please provide email or phone

We do not show your email or contact info

Please accept our Terms & Conditions
Add photos or video
We recommend photos and videos to help explain your report
Use camera
Select from library
Email or SMS copy of report
Enter below to get emailed a copy of your report, or sms a link to your report
Please provide email or phone
Please provide email or phone
Please accept our Terms & Conditions
Thank you for your report!


IMPORTANT - Your report is queued
It may take up to 12 hours to process your report.


Email us at support@safelyhq.com if you have questions.

Report by
Please provide location
Please provide location
Please provide report title
Please provide details
Please accept our Terms & Conditions
Get alerts and updates for your case! Your contact information is not shown on the website.

This information is not shown on the website. We can notify you of updates, and may contact you for more information to help resolve or follow up on your issue.

or
Please provide email or phone
Thank you for your report!

IMPORTANT - YOUR REPORT IS QUEUED - IT MAY TAKE UP TO 12 HOURS FOR YOUR REPORT TO SHOW ON OUR HOME PAGE (IF NOT OPTED AS PRIVATE)

If your report is poison related call 1-800-222-1222 for a free consultation with a live medical poisoning expert

Visit our learn pages for more helpful information or, email us: support@safelyhq.com

Goodbye! and best wishes in your recovery

Covid-19 OSHA Complaint, Mesa Airlines, Inc., 2617 S 46th St, PHOENIX, AZ, 85034, USA

1 week ago

2617 South 46th Street, Phoenix, 85034 Arizona, United States

Item 1: The company training department is placing employees at risk for COVID-19 by not requiring them to wear a mask or cloth coverings. Pilots were recently seen in the class without masks. Item 2: The company training department is placing employees at risk for COVID-19 by not requiring them to social distance while in the training class. Employees are seated right next to each other without a barrier for separation. Pilots were recently seen in class without masks. Item 3: The employer requires flight attendants to share hotel rooms during training and there is no communication on preventing the spread of COVID while they share a space.


Source: Osha.gov | Receipt Date: 2021-03-17

Related Reports

6 individuals at Trailblazer Elementary School in El Paso county tested positive for Covid-19. The outbreak began on 13-09-2021

Source: colorado.gov See Less

15 individuals at Twin Peaks Charter Academy in Boulder county tested positive for Covid-19. The outbreak began on 14-09-2021

Source: colorado.gov See Less

1 individual at UPS - Commerce City in Adams county tested positive for Covid-19. The outbreak began on 26-01-2021

Source: colorado.gov See Less

13 individuals at Vista Ridge High School in El Paso county tested positive for Covid-19. The outbreak began on 01-09-2021

Source: colorado.gov See Less

9 individuals at Watson Junior High School in El Paso county tested positive for Covid-19. The outbreak began on 25-08-2021

Source: colorado.gov See Less

1 individual at West Ridge Elementary School in Adams county tested positive for Covid-19. The outbreak began on 02-09-2021

Source: colorado.gov See Less

7 individuals at William J. Palmer High School in El Paso county tested positive for Covid-19. The outbreak began on 13-09-2021

Source: colorado.gov See Less

5 individuals at Woodland Park High School in Teller county tested positive for Covid-19. The outbreak began on 13-09-2021

Source: colorado.gov See Less

8 individuals at World Compass Academy in Douglas county tested positive for Covid-19. The outbreak began on 31-08-2021

Source: colorado.gov See Less

Recent Interesting Reports

Company name: Teligent Pharma, Inc.
Brand name: Teligent
Product recalled: Lidocaine HCl Topical Solution 4%
Reason of the recall: Super potency
FDA Recall date: August 30, 2021
Recall details: Teligent Pharma, Inc. is voluntarily recalling one lot of Lidocaine HCl Topical Solution 4%, 50ml in a screw... See More cap glass bottle to the user level. The product is being recalled because the firms testing has found it to be super potent based on an Out of Specification (OOS) result obtained at the 18-month stability timepoint.

Risk Statement: Use of the super potent product would result in a higher than intended lidocaine dose above that intended.  An increased lidocaine dose could lead to the development of local anesthetic systemic toxicity depending on the duration of the treatment and the specific patient.  Local anesthetic systemic toxicity can result in central nervous system reactions including excitation and/or depression and more serious signs of cardiovascular toxicity, such as bradycardia, hypotension, and even cardiovascular collapse can present very quickly.

If local anesthetic systemic toxicity is not recognized and treated quickly, severe morbidity and even death can result. Adults and the elderly who are more likely to use this product as well as children of lower body weight are more likely to experience local anesthetic systemic toxicity if a higher than intended lidocaine concentration is administered.

To date, Teligent Pharma, Inc. has not received any reports of adverse events related to this recall. The product is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract and is packaged in a 50ml glass bottle with a screw cap with the identification NDC# 52565-009-50.  The affected Lidocaine HCl Topical Solution 4% lot number and expiration date are:  Lot # 14218, Exp. 09/2022.  The product can be identified by the following labeling:  Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL).  

Product was distributed at the wholesale and retail distribution levels in the US and Canada. Teligent Pharma, Inc. is notifying its distributors via Fed-Ex and is arranging for return of all recalled products. Distributors, consumers, and patients that have Lidocaine HCl Topical Solution 4% which is being recalled should return product to their place of purchase.

Consumers with questions regarding this recall can contact Teligent Pharma, Inc. by phone at 1-856-697-1441 press * to reach the medical information call center Monday through Friday, 8am – 5pm. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Check the full recall details on fda.gov

Source: FDA
See Less

Company name: ICU Medical, Inc.
Brand name: Hospira
Product recalled: Aminosyn II, 15%, An Amino Acid Injection, Sulfite
Reason of the recall: Presence of visible particulate matter
FDA Recall date: September 07, 2021
Recall details: ICU Medical, Inc. is voluntarily recalling one lot (2,112 units) of Aminosyn... See More II, 15%, An Amino Acid Injection, Sulfite Free intravenous (IV) solution to the hospital/user level due to the presence of visible particulate matter identified as fibers, hair, and proteinaceous material along with other particles. 

ICU Medical became aware of this issue while inspecting retain samples as part of routine process. Administration of a drug product that contains particulate matter could result in adverse events ranging from inflammation at the site of injection to more serious events that could include the formation of a blood clot obstructing the flow of blood which could lead to end-organ damage or death. 

To date, ICU Medical, Inc. has not received reports of adverse events or illnesses related to this recall. Aminosyn II, Sulfite-Free, (an amino acid injection) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. 

Aminosyn II can be administered peripherally with dilute (5 to 10%) dextrose solution and I.V. fat emulsion as a source of nutritional support. This form of nutritional support can help to preserve protein and reduce the breakdown of organic or inorganic materials, such as proteins, sugars, fatty acids, etc. in stress conditions where oral intake is inadequate. Aminosyn II is also indicated for central vein infusion to prevent or reverse excreting more nitrogen than is being taken in in patients where the intestinal tract, by the oral, surgical opening into the stomach for the introduction of food or surgical procedure for a feeding tube routes cannot or should not be used and gastrointestinal absorption of protein is impaired. 

Product was distributed nationwide both by ICU Medical direct to customers and through medical distributors. The product is for human use only. ICU Medical acquired this product from Hospira, a Pfizer company; therefore, the affected product contains a Hospira NDC number and a Hospira label. The affected product lot, manufactured in the U.S. by ICU Medical in November 2020, is listed below:  

- Aminosyn® II 15% An Amino Acid Injection, Sulfite-Free. NDC: 0409-7171-17. Catalog Number: 07171-17. Lot Number: 4989094. Expiration Date: 01-Apr-2022. Configuration: Pharmacy Bulk. Package 2-liter. Flexible. Container. Manufacture Date: November 2020. Distribution Dates: January 2021 – March 2021.

ICU Medical is notifying its distributors and customers of this recall by letter and is arranging for the return of all recalled products.

Hospitals/distributors that have a product that is being recalled should stop use/further distribution and return to the place of purchase.

Customers with questions regarding this recall can call ICU Medical at 1-844-654-7780 Monday through Friday between the hours of 8 a.m. and 5 p.m. Central time. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using these drug products.

Check the full recall details on fda.gov

Source: FDA
See Less

I was given the second dose of the vaccine and everything was very fast in the Benalcazar, there was practically no one and a side effect I only had a little pain in my arm for a day and a half | Symptoms: Soreness See Less

I ordered a wood cutter, chain saw, rechargeable on 3/18/21.  The linked showed up on Facebook.  I did not receive my chain saw.  Apparently the company, Amphitrite Technology Limited has been scamming people all year.  It wasn’t until I found your website that I realized I had... See More been sent this weird chain, hand cutter.  There are many pictures posted on your site of the same product.  I had no idea why this thing came to me.  I did not think it was a “replacement” or substitute for the little chain saw that was rechargeable.   

I can see there are several posts about the same problem. What can be done? Why has PayPal continued to allow the seller to sell? What can you do? What can I do, to stop others from the company”s fraud?

I purchased through PayPal; directly after this purchase my bank notified me that someone tried to buy a cell phone. What happens next? With so many reports of fraud, why hasn’t the seller been reported to officials? What can you do? What can I do on my part? I contacted PayPal. The company should be blocked from selling
See Less

PetSmart, in cooperation with the Consumer Product Safety Commission (CPSC), announced a voluntary recall of more than 100,000 of the Top Paw® Double Diner Dog Bowl after learning of a potential risk of laceration if the gasket on the bottom of the product comes off, leaving an... See More unfinished edge. No other products are affected by this recall.

According to CPSC, PetSmart has received three reports of consumers receiving cuts and scratches after handling the bowls with the unfinished edge.

- Top Paw® Double Diner Dog Bowl. SKU: 5270098. UPC: 73725775404

The recalled product is described as a set of two elevated metal dog food bowls that sit in a metal base surrounded by a plastic gasket. The bowls were sold at the pet stores from October 2017 through June 2021.

The company advises consumers to immediately stop using the recalled product and to the nearest PetSmart for a full refund.

Source: petsmartcorporate.com
See Less

Some individuals are fearing maybe the vaccines contain virus

Some people are not willing to be vaccinated against the virus which sometimes may lead to the rapid spread of the virus See Less

I saw an ad on the internet for a mini chainsaw called rosespros.
I paid $25.99 for it in May.
They took my money but I've never recieved the saw.

I'm so tired of being scammed by these crooked companies that float around on the internet and... See More basically steal from people. I ordered from an ad that popped up when I was playing a game See Less

Company name: Pfizer
Brand name: CHANTIX
Product recalled: Varenicline tablets
Reason of the recall: N-nitroso-varenicline above acceptable daily intake level
FDA Recall date: September 16, 2021
Recall details: Pfizer is voluntarily recalling all lots of Chantix 0.5 mg and 1 mg Tablets to the patient (consumer/user) level... See More due to the presence of a nitrosamine, N-nitroso-varenicline, at or above the FDA interim acceptable intake limit. As alternative suppliers have been approved in the United States, Pfizer is undertaking this precautionary measure. Long-term ingestion of N-nitroso-varenicline may be associated with a theoretical potential increased cancer risk in humans, but there is no immediate risk to patients taking this medication. Check the link below for the full list of the recalled products.

The health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline. Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. Everyone is exposed to some level of nitrosamines. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time.

Chantix is a treatment to help patients quit smoking and is intended for short-term use. People who smoke cigarettes are 15 to 30 times more likely to get lung cancer than people who do not smoke.

Smoking is also associated with many other cancers, as well as with cardiovascular disease and lung disease. CHANTIX has a safety profile that has been established over 15 years of marketing authorization and through a robust clinical program. Pfizer believes the benefit/risk profile of CHANTIX remains positive. Patients currently taking Chantix should consult with their healthcare provider about alternative treatment options.

To date, Pfizer has not received reports of adverse events assessed to be related to this recall. The NDC, Lot Number, Expiration Date, and Configuration details for Chantix Tablets are indicated in Appendix A. Photos of the products can be found in Appendix B.

The products were distributed nationwide to Wholesalers and Distributors in the United States, US Virgin Islands, and Puerto Rico from May 2019 to September 2021. Pfizer places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process. Pfizer has notified their direct consignees by letter to arrange for return of any recalled product.

Wholesalers and Distributors with an existing inventory of Chantix tablets, should stop use and distribution and quarantine the product immediately. If you have further distributed the recalled product, please notify any accounts or additional locations which may have received the recalled product from you. Please conduct a sub-recall to those accounts and communicate this recall information immediately.

If you received free product through the Pfizer Patient Assistance Program (PAP) or the Pfizer Institutional Patient Assistance Program (IPAP), please check your stock immediately. Additionally, if you are aware of any patients to whom you dispensed the products and who still may have the product in their possession, please ask them to return the product.

As communicated by FDA, there is no immediate risk to patients taking Chantix.iv Patients who are taking this product should consult with their health care provider to determine if alternative treatments are available.

Check the full recall details on fda.gov

Source: FDA
See Less

Scam Hahdi, CT, USA

2 weeks ago

I ordered the battery powered chain saw on May 9th and still have not received it. I would like my money back. Hahdiy
Not sure being it was so long ago See Less